GENEURO

GeNeuro is a Swiss-based clinical stage company committed to bringing safe and effective solutions for stopping the progression of the disability caused by autoimmune diseases, starting with Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS)... GeNeuro is testing temelimab, a monoclonal antibody targeting HERV-W Env, a HERV protein which is found in the brain of MS patients and has been showed to be capable of fueling important mechanisms behind the build-up of brain damage and disability. Temelimab has already shown on 200+ patients for two years that it has a coherent impact across all key MRI markers associated with disease progression. Temelimab has also been succesfully tested at the Karolinska Institutet's Academic Specialist Center in Stockholm on a cohort of patients experiencing disability progression in the absence of relapses, due to a concomitant treatment with an efficacious anti-inflammatory drug, to confirm its potential against the progression of..

Also known as: GeNeuro SA

Primary location: Plan-les-ouates Switzerland